The prognosis in Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) is a matter of debate. Our aim was to assess long-term outcomes of patients with MOGAD.
We retrospectively analysed clinical and paraclinical data of patients who tested positive for MOG-IgG and had clinical follow-up of at least 8 years from their first episode, from the French nationwide observatory study NOMADMUS.
Sixty-one patients (median age at onset 27, range 3-69) with median follow-up of 177 months (mean 212.8, range 98-657) were included. Among 58 patients with a relapsing course, 26.3% relapsed in the first year from onset. Of the 61 patients, 90.2% experienced at least one episode of optic neuritis. At last visit, the median EDSS was 1 (mean 2.12; range 0-7.5), 12.5% had an EDSS ≥6 and 37.5% had an EDSS ≥3. Of 51 patients with final visual acuity available, 15.7% had visual acuity ≤0.1 in at least one eye and 25.5% had visual acuity ≤0.5 in at least one eye. Bilateral blindness (visual acuity ≤0.1) was present in 5.9% of patients. Finally, 12.5% of patients presented bladder dysfunction requiring long-term urinary catheterization. No factor associated significantly with a final EDSS ≥3 or with final visual acuity ≤0.1 was found.
Overall long-term favourable outcomes were achieved in a majority of our patients, but severe impairment, in particular visual damage, was not uncommon.